RxLink Pharmacy Franchise Services

RxLink - Spirit of the Independent Pharmacist!



Pharmacy News

Drug Updates

HMO News

Events for Pharmacists

Clinical Pharmacy

Compounding Pharmacy

HomeCare Pharmacy

Long-Term Care 

RxLink Nutrition


RxLink - A Great Link for the IPhBOs (Independent Pharmacy Business Owners)




RE: Mirapex (pramipexole dihydrochloride) tablets


The purpose of this letter is to advise you that effective May 1, 2005, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), will be the exclusive promoter of Mirapex (pramipexole) in the US. As such, BIPI's newly expanded Neurology sales force will be responsible for all field support on this brand; the Pfizer field force will no longer be providing field support for the product.

This was a joint decision made by BIPI and Pfizer. The companies have been working together to ensure that the transition occurs without disruption to patients, caregivers and healthcare professionals. The change will have no impact on the availability of your retail stocking or sales of MIRAPEX. Please note that the MIRAPEX label will change and the wording "co-marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc," will be removed.

We are excited about this transition to our expanded Neurology sales force. It is our strong belief that this expansion will help assure the continued growth of the MIRAPEX brand. We look forward to working with our retail partners to ensure that this transition goes smoothly.


Robert W. Belknap

Executive Director, Trade Relations

Boehringer Ingelheim Pharmaceuticals, Inc.


© 2004 RxLink - All Rights Reserved. RxLink is designed by Pharmacists for Pharmacists & Pharmacy Techs.  For information use only! Disclaimer.

RxLink.Biz  RxLink LLC - RxLink Pharmacy Franchise Services © 2007 All Rights Reserved